LAG3 and ovarian carcinoma: These studies underscore the potential of anti-LAG-3 therapy to enhance the outcomes of solid tumors with high LAG-3 expression, particularly those exhibit suboptimal response or resistance to anti-PD-1 therapy, such as ovarian epithelial cancer and triple-negative breast cancer [250, 261, 262].